Johnson & Johnson Portfolio Concentration: Heavy Exposure in Healthcare Stocks

Johnson & Johnson holds a significant investment portfolio valued at $695.9 million as of June 30, 2026.

The investor's holdings are characterized by extreme concentration, with all assets allocated to the Healthcare sector according to the sector_allocations data provided.

This single-sector focus is evident in their top holdings. The largest position, symbolized by PTGX (PROTAGONIST THERAPEUTICS INC), accounts for 37.59% of the portfolio's value and represents a substantial investment of $300.2 million.

Secondly, NBTX (NANOBIOTIX) holds significant weight at 26.55%, with its stock value totaling $212.0 million. Other major positions include RAPP (9.31%), CTNM (4.06%), and LEGEND BIOTECH CORP (LEGN, 2.95%).

While the portfolio includes several other holdings like CVRX, XNCR, FATE, PRCT, and NMRA, their combined weight is less than 13%. This indicates that Johnson & Johnson's investment strategy relies heavily on a small number of large positions within Healthcare.

The complete lack of position changes from the prior period (change_in_shares_from_prior_period: 0 for all holdings) suggests stability in these major investments, despite fluctuations potentially occurring elsewhere in the portfolio which are not detailed here.